跳至主要内容
临床试验/CTRI/2018/03/012292
CTRI/2018/03/012292已完成2 期

Clinical Evaluation of Rasnadi Kvatha Churna (Maha), Trayodashanga Guggulu and Brihatsaindhavadya Taila in the Management of Osteoarthritis of Knee (Janugata Sandhivata)

Central Council for Research in Ayurvedic Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1)Patients of either sex aged between 35 and 65 years.
  • 2)Patient with Primary Osteoarthritis (knee joints) fulfilling the diagnostic criteria of osteoarthritis recommended by the American College of Rheumatology. (ACR clinical classification criteria)
  • Knee pain and at least three of the following 6 criteria:
  • i.50 years of age or older
  • ii.Stiffness lasting less than 30 minutes
  • iii.Crepitus
  • iv.bony tenderness
  • v.bony enlargement
  • vi.no warmth to the touch
  • 3)With radiological changes as per Grade I to III of Kellgren & Lawrence Radiological scale)
  • Kellgren & Lawrence Radiological scale
  • Grade 1: Narrowing is defined as doubtful narrowing of joint space and possible osteophytic lipping.
  • Grade 2: Osteophytes and definite narrowing of joint space.
  • Grade 3: Moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone ends.
  • Grade 4: Large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone contour.
  • 4) Willing and able to participate in the study for 16 weeks.

排除标准

  • 1)Patients with Grade IV Kellgren & Lawrence Radiological scale.
  • 2)History of any trauma / fractured joint / surgical / diagnostic intervention with reference to the affected joint(s).
  • 3)Gross disability in performing daily normal routine i.e. bedridden patients or confined to a wheelchair.
  • 4)Patients with co-morbidities such as gouty arthritis, rheumatoid arthritis and psoriatic arthritis.
  • 5)Patients having any deformity of knee, hip or back altering the gait and posture of the patient.
  • 6)Patients with uncontrolled hypertension ( >160/100 mm of Hg).
  • 7)Patients with uncontrolled diabetes mellitus HbA1C > 7%
  • 8)Patients with evidence of malignancy.
  • 9)The patient has been administered any chondroprotective drugs, intra-articular injection into the affected joint.
  • 10)Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics etc. or any other drugs that may have an influence on the outcome of the study.
  • 11)Patients who have a past history of atrial fibrillation, acute coronary syndrome, myocardial infarction, stroke or severe arrhythmia in the last 6 months.
  • 12)Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]).
  • 13)Pregnant / lactating woman.
  • 14)Patients who are currently participating in any other clinical trial.
  • 15)Patients who have completed participation in any other clinical trial during the past six months
  • 16)Any other condition which the Principal Investigator thinks may jeopardize the study.

研究者

相似试验